Fornander T, Rutqvist L E, Glas U
Cancer Treat Rep. 1987 Jul-Aug;71(7-8):685-8.
The response to tamoxifen or a combination of tamoxifen and fluoxymesterone was assessed in 54 postmenopausal breast cancer patients with recurrent disease. The patients had originally been entered in a randomized trial of 2 years of tamoxifen (40 mg daily), as an adjunct to primary surgery, versus no adjuvant endocrine therapy. The objective response rate (complete + partial) to the mentioned salvage endocrine therapies was significantly lower among patients from the tamoxifen group as compared to the controls (14% vs 54%; P less than 0.01). Their median time to disease progression was also significantly shorter (4 vs 15 months; P less than 0.05). Differences between the groups in regard to prognostic factors could not explain these differences. The lower response rate to these endocrine treatments was possibly one reason for the poorer survival outlook after relapse observed among the patients previously treated with adjuvant tamoxifen. An increased relapse-free survival achieved with adjuvant therapy may thus to some extent be offset by a poorer survival after relapse.
对54例绝经后复发性乳腺癌患者评估了他莫昔芬或他莫昔芬与氟甲睾酮联合用药的疗效。这些患者最初参加了一项随机试验，比较2年他莫昔芬（每日40毫克）作为原发性手术辅助治疗与不进行辅助内分泌治疗的效果。与对照组相比，他莫昔芬组患者对上述挽救性内分泌治疗的客观缓解率（完全缓解+部分缓解）显著较低（14%对54%；P<0.01）。他们疾病进展的中位时间也显著更短（4个月对15个月；P<0.05）。两组在预后因素方面的差异无法解释这些差异。对这些内分泌治疗的较低缓解率可能是先前接受辅助他莫昔芬治疗的患者复发后生存前景较差的一个原因。因此，辅助治疗实现的无复发生存期增加可能在一定程度上被复发后较差的生存率所抵消。
